Key facts
- This page summarizes David M. Berman's Form 4 filing for Immunocore Holdings plc (IMCR).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Feb 2025, 16:18.
David M. Berman - 17 Feb 2025 Form 4 Insider Report for Immunocore Holdings plc (IMCR)
- Reporting relationship
- HEAD OF R&D
- Issuer ticker
- IMCR
- Reported as of
- 17 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 19 Feb 2025, 16:18:07 UTC
- Prior SEC filing
- 01 Mar 2024
- Next SEC filing
- 12 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lily Hepworth, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David M. Berman filed Form 4 for Immunocore Holdings plc (IMCR) on 19 Feb 2025.
Change
- Previous filing in this sequence was filed on 01 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IMCR
transaction
Derivative
Employee Share Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +129,518
- Change %
- Price
- $0.000000
- Shares after
- 129,518
- Date
- 17 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 129,518
- Exercise price
- $29.60
- Footnotes
- F1
IMCR
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +47,297
- Change %
- Price
- $0.000000
- Shares after
- 47,297
- Date
- 17 Feb 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 47,297
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
25% of the shares subject to the option award shall vest on February 17, 2026, and 6.25% of the shares subject to the option award shall vest in quarterly installments thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Footnote F2
Each restricted share unit ("RSU") represents a contingent right to receive one ordinary share.
Footnote F3
The RSUs vest in four equal annual installments beginning February 17, 2026, subject to the Reporting Person's continuous service through each such vesting date.